Pharma stock jumps 3% after receiving USFDA approval for diabetes insulin drugPharma stock jumps 3% after receiving USFDA approval for diabetes insulin drug

Introduction:

Leading global pharma company has received U.S. FDA approval for the first interchangeable rapid-acting insulin Aspart, expanding its diabetes portfolio and enhancing treatment options for patients in the United States.

Also Read: Consumer Electronics stock jumps 4% after entering into agreement to acquire 51% stake in Kunshan Q Tech Electronics

Share price movement of Biocon:

On July 16, 2025, Biocon Ltd opened at ₹399.05, 2.30% up from its previous close of ₹390.20. The stock touched a high of ₹405.85 and a low of ₹393.25. By 11:23 AM, it was trading at ₹395.75, marking a 1.42% gain, with a full market capitalization of ₹52,910.34 crore.

Biocon Biologics Receives FDA Nod for Interchangeable Insulin Aspart:

Biocon Biologics Ltd, a global biosimilars company and subsidiary of Biocon Ltd, announced FDA approval for Kirsty™, a biosimilar to NovoLog®, used to manage blood sugar in diabetes patients.

Kirsty™ is the first and only interchangeable biosimilar rapid-acting insulin Aspart approved in the U.S. It will be available in both prefilled pens for subcutaneous use and vials for subcutaneous and intravenous administration.

This approval expands Biocon Biologics’ diabetes care portfolio, which includes Semglee®, another FDA-approved interchangeable biosimilar insulin. Kirsty™ has been previously launched in Europe and Canada and now strengthens the company’s presence in the U.S. insulin market.

Recent news on Biocon:

As of June 20, 2025, Biocon Ltd successfully raised ₹4,500 crore via QIP, issuing 13.63 crore shares at ₹330 each, reflecting strong interest from both domestic and international institutional investors.

Stock performance of Biocon for Period of 1 week, 6 months, and 1 year:

Biocon Ltd delivered a 4.52% return over the past week, declined by 0.83% in the past six months, and gained 10.5% over the past year.

Also Read: Monika Alcobev IPO: Check the latest GMP for Monika Alcobev IPO here

Shareholding pattern of Biocon:

Particulars	Jun 19, 2025	Mar 2025	Dec 2024
Promoter	54.50%	60.60%	60.60%
FII	7.00%	5.70%	5.70%
DII	21.50%	15.70%	15.40%
Public	16.90%	17.80%	18.10%
Others	0.20%	0.20%	0.20%

About Biocon:

Biocon Ltd (NSE: BIOCON), listed in 2004, is a global biopharmaceutical company developing novel biologics, biosimilars, and complex APIs, focused on affordable therapies for diabetes, cancer, and autoimmune conditions across major global markets.

Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time. The securities quoted are exemplary and are not recommendatory.